Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Blood Cancer Discov. 2022 Mar 1;3(2):87-89. doi: 10.1158/2643-3230.BCD-21-0200.
In this issue of Blood Cancer Discovery, Zheng and colleagues identify that alternative RNA splicing of CD22 within B-cell acute lymphoblastic leukemia can result in antigen escape from CD22-targeted immunotherapies. Drug-resistant isoforms of CD22 exist within leukemic cells pretreatment and can influence response to the CD22-directed antibody-drug conjugate inotuzumab ozogamicin, the immunotoxin moxetumomab pasudotox, as well as anti-CD22 chimeric antigen receptor T cells. See related article by Zheng et al., p. 103 (7).
在本期《Blood Cancer Discovery》中，Zheng 及其同事确定，B 细胞急性淋巴细胞白血病中 CD22 的选择性 RNA 剪接可导致抗原逃避 CD22 靶向免疫疗法。在白血病细胞预处理时存在 CD22 耐药性同工型，可影响对 CD22 导向抗体药物偶联物伊妥珠单抗奥佐米星、免疫毒素莫昔妥莫单抗帕苏妥昔、以及抗 CD22 嵌合抗原受体 T 细胞的反应。详见 Zheng 等人的相关文章，第 103 页（7）。
